JUL 28, 2014 12:00 AM PDT

Cortellis Reaches Milestone

WRITTEN BY: Ilene Schneider
The Intellectual Property and Science business of Thomson Reuters, a leading provider of intelligent information for businesses and professionals, announced that Cortellis Clinical Trials Intelligence, its global clinical-drug-trial intelligence database, marked an industry-first milestone with the documentation of more than 180,000 clinical trials.

The database is designed to provide pharmaceutical professionals with greater and quicker access to critical data and strategic insights to build stronger, more effective clinical trials. Launched in August 2013, it is part of the Cortellis suite, a source of life sciences intelligence information and analytics across multiple disciplines including regulatory, business development, discovery and pre-clinical.

Thomson Reuters' Cortellis Clinical Trials Intelligence gives life science professionals access to information and analytics from more than 180,000 global clinical trials, including coverage of drugs, biologics, diagnostics, biomarkers and medical devices, supporting a wide range of outcome searching. Cortellis users can gain deeper scientific and competitive insights by connecting clinical trial data with drug pipelines, patents, pre-clinical insights and biomarkers on a single, unified platform, reducing time spent compiling and analyzing clinical information, and to ultimately construct better trials. The information can also be accessed through APIs embedded in a customer's existing workflow or third-party software applications.

"We are proud to have reached this significant industry milestone within the first year of releasing Cortellis Clinical Trials Intelligence," said Jon Brett-Harris, managing director, Thomson Reuters IP & Science. "This rapid development is a reflection of our continued commitment to provide the best available information to support the pharmaceutical industry in driving successful clinical trials."

Cortellis Clinical Trial Intelligence makes program planning and competitive research simpler and more efficient as the number of clinical trials in the database continues to grow. The solution also allows users to discover competitor strategies for specific patient segments, biomarker utilization, end points and novel insights into disease processes and to uncover vital connections by integrating their internal, proprietary data with the wide variety of reference information available through Cortellis.

Thomson Reuters is a leading source of intelligent information for businesses and professionals. The company combines industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by a long-established's most trusted news organization.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Learning More About Changes in Cancer Cell Identity
Cancer cells can change their identity and can take on new functions and characteristics, which is often rooted in epigenetic alterations....
DEC 15, 2019
Cannabis Sciences
DEC 15, 2019
Masters in Cannabis Open for Enrollment!
If you’ve been waiting to study medical cannabis sciences at the college level, your time has come. A pharmaceutical studies program leading to an MS...
DEC 15, 2019
Cell & Molecular Biology
DEC 15, 2019
New Insight Into Chronic Pain May Help Create Novel Therapeutics
Acute pain can progress to chronic pain, which can cause other problems including depression, loss of motivation and sensory dysfunction....
DEC 15, 2019
Health & Medicine
DEC 15, 2019
Study finds association between hair products and breast cancer risk
For many women, hair color and style are significant components of their identity. However, troubling information from a new study about the use of hair dy...
DEC 15, 2019
Drug Discovery & Development
DEC 15, 2019
Parkinson's Drug Reduces Hallucinations in Dementia Patients
Pimavanserin, also known as Nuplazid, was approved in the US to treat Parkinson’s-related psychosis in 2016. Now, new research has shown that it also...
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
The Cause of a New Autoimmune Disease is Discovered
Researchers have discovered a new autoinflammatory disease, which they have called CRIA (cleavage-resistant RIPK1-induced autoinflammatory) syndrome....
Loading Comments...